# IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

> **NCT05136924** · PHASE2 · UNKNOWN · sponsor: **Vance Thompson Vision - MT** · enrollment: 20 (estimated)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo
- **OTHER:** Placebo (vehicle) nasal spray

## Key facts

- **NCT ID:** NCT05136924
- **Lead sponsor:** Vance Thompson Vision - MT
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05136924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05136924, "IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05136924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*